---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical presentation - signs and symptoms"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical presentation - signs and symptoms. Topics: Central vision: scotoma and progressive central visual field loss, Central vision: symptom onset and course compared with neovascular AMD, Visual acuity: preserved acuity with foveal sparing and loss with central involvement, Reading: reduced maximum reading rate in eyes with good visual acuity, and 9 further topics. 13 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/clinical-presentation-signs-and-symptoms"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical presentation - signs and symptoms

<a id="heading-2.2.1.6"></a>

## 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

### Central vision: scotoma and progressive central visual field loss

> “Although GA can result in significant visual function deficits in reading, night vision, and dark adaptation, and produce dense, irreversible scotomas in the visual field, the initial decline in VA may be relatively minor if the fovea is spared.”

Source: [Holz et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24433969/)

> “Areas of GA enlarge over time, leading to progressive central visual field loss”
> “Central visual loss is typically related to late AMD stages associated with photoreceptor loss. When the areas of photoreceptor loss expand, patients often lose central vision, markedly decreasing the ability to read or recognize faces.”

Source: [Fleckenstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12878645/)

<a id="topic-2.2.1.6-2"></a>

### Central vision: symptom onset and course compared with neovascular AMD

| Stage | Clinical manifestation |
| --- | --- |
| Geographic atrophy | “Symptom onset and progression rather slow: distortion, decline in vision, and/or central visual field defects” |
| Exudative neovascular AMD | “Symptoms may occur suddenly with rapid worsening: distortion, decline in vision, and/or central visual field defects” |

Source: [Fleckenstein et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12935482/)

<a id="topic-2.2.1.6-3"></a>

### Visual acuity: preserved acuity with foveal sparing and loss with central involvement

> “The presence of GA in the central 1-mm zone of the macula correlates with reduced VA, whereas total geographic atrophy area correlates poorly to VA.”
> “Eyes with GA outside the fovea maintain relatively good VA, yet patients’ quality of life can be affected because the inner left subfield is associated with reading and the inner lower subfield is associated with distance vision activities.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

<a id="topic-2.2.1.6-4"></a>

### Reading: reduced maximum reading rate in eyes with good visual acuity

> “Half the eyes with GA, but none of the drusen eyes, had maximum reading rates below 100 words per minute.”
> “The eyes with GA with good VA have profound decreases in visual function, particularly in dim lighting and in reading.”

Source: [Sunness et al. (1997)](https://pubmed.ncbi.nlm.nih.gov/9331210/)

<a id="topic-2.2.1.6-5"></a>

### Reading: difficulty with reading as the main patient complaint

> “The main complaint among patients was difficulties regarding daily tasks, especially reading and other near activities.”

Source: [Krogh Nielsen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37933609/)

> “All participants had issues with reading since the onset of GA. Many participants had reluctantly given up reading for pleasure, mainly because it took a lot longer.”
> “When it came to reading for necessity, participants had difficulties with reading menus, reading sell-by dates, prices and other information on products, and using card machines in shops.”

Source: [Carlton et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7510394/)

<a id="topic-2.2.1.6-6"></a>

### Low-luminance vision: worse function in dim light and its predictive value

> “These endpoints are of particular interest because patients with AMD, especially those with GA, often experience worse functional difficulties in dimly lit environments than in bright conditions”

Source: [Lad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12882265/)

> “The baseline low-luminance deficit (LLD) in VA was a strong predictor of subsequent VA loss for all levels of baseline VA. Within the good baseline VA group, the relative risk (RR) of 3-line loss for the worse LLD group compared with the better LLD group was 2.88 (95% confidence interval [CI], 1.13-7.35).”

Source: [Sunness et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18486216/)

> “The worsening of VA in decreased luminance and foveal dark-adapted sensitivity showed severe abnormalities for the GA group. Contrast sensitivity was significantly reduced for the eyes with GA.”

Source: [Sunness et al. (1997)](https://pubmed.ncbi.nlm.nih.gov/9331210/)

<a id="topic-2.2.1.6-7"></a>

### Dark adaptation: delayed recovery after exposure to bright light

> “In the early stages of AMD, patients commonly experience alterations in visual function characterized by a delay in dark adaptation; diminished sensitivity to contrasts; and, subsequently, the appearance of scotomas in their central visual field. As the area of atrophy increases to involve larger areas of the central retina, patients begin to experience a more pronounced deterioration in central visual acuity, slower reading speed, distorted vision, challenges in discerning colors, extremely slow recovery in dark adaptation following exposure to bright light, and substantial impairment of overall visual function”

Source: [Lad et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12882265/)

> “Additionally, changes in dark adaptation may occur despite stability in BCVA, suggesting better sensitivity in the assessment of visual function loss in patients with GA”

Source: [Li et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12976467/)

<a id="topic-2.2.1.6-8"></a>

### Face recognition: difficulty recognizing faces with central field loss

> “Participants in both groups were affected by a range of symptoms from GA with most experiencing varying levels of disrupted peripheral and central vision; intolerance to brightness and glare; dizziness and problems with face recognition.”

Source: [Carlton et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7510394/)

> “GA is known to cause significant functional and psychosocial burden, where patients with subfoveal GA struggle with facial recognition, driving and navigation, and parafoveal GA causing significant issues with reading and complex visual scenes”

Source: [Li et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12976467/)

> “Patients may have difficulty with seeing faces, reading whole words rather than the single letters used in visual acuity assessments, and performing fine motor tasks like sewing.”

Source: [Baker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13546186/)

<a id="topic-2.2.1.6-9"></a>

### Light sensitivity and other patient-reported symptoms: concept elicitation interviews

> “In total, 25 symptoms and 36 impacts were reported by 19 patients with GA, with seven symptoms and 11 impacts identified as salient.”
> “The symptoms with the highest average disturbance rating were night blindness, general fatigue, dry eyes, and sleep disturbance.”
> “The impacts with the highest average disturbance rating were fear, difficulty driving, and difficulty reading.”
> “Of these VISSA-10 items, blurry vision, poor light adaptation, defective color vision, and sensitivity to brighter light have been reported by patients with GA in previous studies, but the saliency of these symptoms was not measured”

Source: [Morga et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10011295/)

<a id="topic-2.2.1.6-10"></a>

### Driving: visual acuity below the driving standard at diagnosis of bilateral GA

> “At first record of GA, 7.1% had a VA in the better-seeing eye equal to or lower than the cutoff for blindness registration and 71.1% had a VA that would have rendered them ineligible to drive.”

Source: [Chakravarthy et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29366564/)

<a id="topic-2.2.1.6-11"></a>

### Perceptual symptoms: Charles Bonnet syndrome visual hallucinations

> “The prevalence of CBS was 25 in 120 (20.8%). Thirteen (52%) of those with CBS were not previously informed of the disease.”
> “One in five with GA has CBS, which ranks GA as an eye disease with one of the highest reported prevalences of CBS.”

Source: [Eriksen et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11736733/)

<a id="topic-2.2.1.6-12"></a>

### Emotional symptoms: fear, frustration, and anxiety

> “However, a large proportion of patients also reported fear, frustration, and anxiety as salient symptoms with large impact.”

Source: [Krogh Nielsen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37933609/)

> “emotions experienced included fear and frustration, and these frequently crossed over into their relationships with others”

Source: [Carlton et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7510394/)

<a id="topic-2.2.1.6-13"></a>

### Clinical signs: well-demarcated atrophy with visible choroidal vessels

> “GA has traditionally been defined on color fundus photographs (CFP) as a sharply delineated circular or oval area of hypopigmentation or depigmentation in which choroidal vessels are visible.”

Source: [Guymer et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7218279/)

Additional sources: [Heier et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32199866/)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
